Business Wire

EGON-ZEHNDER

7.3.2024 09:31:29 CET | Business Wire | Press release

Share
New Global Survey from Egon Zehnder Reveals the CFO Role is Bigger Than Ever, “Super CFOs” Continue to Evolve Beyond Finance, Aspire to be CEO

Egon Zehnder, the world’s preeminent leadership advisory firm, today announced the results of a study that surveyed 581 CFOs worldwide to capture how the role of the chief financial officer has shifted over the past five years. The findings demonstrate a major evolution that has “Super CFOs” tackling new challenges, addressing new priorities, and aspiring even more for the CEO role.

Of the nearly 600 CFOs studied, 82% reported that their role has grown significantly, with the vast majority of CFOs citing how new complexities across environmental, social, and governance matters, mergers and acquisitions, and corporate strategy are driving sweeping change - and opportunity - within their role.

“Our study reveals a momentous evolution with ‘Super CFOs’ not just reacting to the changing business environment, but in fact driving it,” said Arun Dhingra, Global Head of Egon Zehnder’s CFO & Audit Chair Practice. “Through my work, I’ve witnessed this transformative era firsthand, and our CFO study reaffirms the reality that the complexities of the CFO role have propelled these leaders to the forefront of their organizations due to the profound shift in their priorities and substantial growth in their role.”

Guiding the Business: 82% of CFOs report they have taken on new responsibilities that were not part of their remit just five years ago

As business dynamics have changed over the past five years, so too has the nature of the CFO’s workload. When asked what new responsibilities have been added to their plate, CFOs ranked ESG, M&A, and corporate strategy as the top three – signaling not only a reaction to shifting industry and market priorities but new reliance upon CFOs as strategic partners to the CEO and the board. This drastic increase in scope is inspiring CFOs to consider their roster of priorities and what could be excluded from their remit in favor of more pressing tasks. As their mandates expand, nearly half (47%) of CFOs report needing to allocate more time to business strategy to meet the new expectations demanded from them.

Looking to the future, the trend of increased responsibilities is expected to continue. When asked about the competencies that will matter most over the next five years, CFOs ranked driving change, shaping strategy, and developing talent as the most important. In particular, female CFOs were adamant about driving change—57% named this the key competency compared to 40% of male CFOs.

Leading their People: Over 40% of CFOs say it is harder to attract top financial talent today compared to two years ago

While CFOs would like to allocate additional time to strategy and talent development, CFOs view finding talent and IT as least central to the future remit of the role. Two-fifths of CFOs agree that it’s harder to attract top financial talent today than it was two years ago.

Over half of CFOs surveyed are ensuring they’re building and developing the right bench by employing the following strategies – more open and honest feedback to the team, rotating top talent throughout various financial roles, and targeted development programs. CFOs largely agree the top two team members they rely on the most are the Head of FP&A and the Controller/CAO. For finance professionals aspiring to become a CFO, when reflecting on their first CFO role, respondents identified board interaction, external credibility with investors, and co-leadership of the organization with the CEO as key areas that required the most growth.

Managing their Careers: 62% of CFOs want to be chief executives at some point in their career, with 7 in 10 reporting they feel prepared to take on the role now

CFO sentiments are also shifting and expanding when it comes to personal career aspirations. While an expanded, more multifunctional CFO role may help them seize those new opportunities – nearly half say networking and visibility is a major barrier to becoming CEO. What’s more, 44% of CFOs are being approached more often for opportunities, a sign that the significant level of CFO departures seen in 2023 is not slowing down. Among CFOs who reported being approached the most, recruitment outreach is especially strong for female CFOs – women reported being reached out to more often (17%) when compared to men (12%), a sign that organizations are continuing to prioritize gender diversity within the C-Suite.

With growing competition for CFO talent, 60% of respondents say they value a high-quality executive team as well as growth prospects (for 45% of respondents) when considering whether to pursue a new opportunity. The focus on whom they’ll work with, over company valuation and revenue, signals that companies that are more intentional about executive development are better positioned to attract top talent than those that aren’t.

“Maintaining the role of corporate ‘Superhero’ is no easy feat,” said James Stark, lead author of the Super CFO Survey and consultant in the CFO & Audit Chair Practice at Egon Zehnder. “As signs point to the CFO role continuing to grow in complexity, financial leaders will need to keep growing their leadership skills to drive success in their current role – and to help them reach the next step in their career trajectory. From talent development to leading their organization's ESG initiatives, the role of the CFO today is a central figure in charting sustainable growth and ensuring organizational resilience in any industry.”

For more information on Egon Zehnder’s services and the study cited in this press release, please visit www.egonzehnder.com/the-super-cfo.

About Egon Zehnder

Egon Zehnder is the world’s preeminent leadership advisory firm, inspiring leaders to navigate complex questions with human answers. Our 600 consultants across 64 offices and 36 countries are former industry and functional leaders who collaborate seamlessly to deliver the full power of the Firm to every client, every time. We believe that together we can transform people, organizations and the world through leadership. For more information, visit www.egonzehnder.com and follow us on LinkedIn and X.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306711015/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye